GH Research (GHRS) Non-Current Deferred Tax Liability (2024 - 2025)
GH Research (GHRS) recorded quarterly Non-Current Deferred Tax Liability of $200000.0 in Q4 2025, down 81.82% quarter-over-quarter from $1.1 million in Q4 2024, and down 81.82% on a YoY basis from $1.1 million in Q4 2024.
GH Research (GHRS) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
GH Research's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $200000.0 for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability fell 81.82% year-over-year to $200000.0; the TTM figure through Dec 2025 stood at $200000.0 (down 81.82% YoY), while the FY2025 annual figure was $200000.0, down 81.82% from the prior year.
- Non-Current Deferred Tax Liability was $200000.0 for Q4 2025 at GH Research, down from $1.1 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q4 2024 to a low of $200000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |